---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009148"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:10:55.548746+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Surrozen reports Q1 2022 results; Phase 1 trials on track for Q3

## Summary
- Q1 financial results announced; no specific revenue or loss figures in the press release excerpt.
- On track to initiate Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in Q3 2022.
- Presented preclinical data for SZN-413 (retinal vascular diseases) at ARVO showing Wnt activation and vessel regrowth.
- Preclinical data for lacrimal gland and lung Wnt modulation highlighted.

## SEC filing metadata
- accession: 0000950170-22-009148
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017022009148/0000950170-22-009148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017022009148/srzn-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009148
- JSON: https://secwatch.observer/filing/0000950170-22-009148.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.